Literature DB >> 24157581

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.

P Jain1, H Kantarjian1, F Ravandi1, D Thomas1, S O'Brien1, T Kadia1, J Burger1, G Borthakur1, N Daver1, E Jabbour1, M Konopleva1, J Cortes1, N Pemmaraju1, M A Kelly1, M Cardenas-Turanzas1, R Garris1, S Faderl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24157581     DOI： 10.1038/leu.2013.312

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Pro-T ALL: immunophenotypical analyses.

Authors:  M C Béné
Journal:  J Biol Regul Homeost Agents       Date:  2004 Jul-Dec       Impact factor: 1.711

2.  Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.

Authors:  Edouard Forcade; Thibaut Leguay; Norbert Vey; André Baruchel; Jacques Delaunay; Marie Robin; Gérard Socié; Hervé Dombret; Régis Peffault de Latour; Emmanuel Raffoux
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-03       Impact factor: 5.742

3.  Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Kimberly P Dunsmore; Meenakshi Devidas; Stephen B Linda; Michael J Borowitz; Naomi Winick; Stephen P Hunger; William L Carroll; Bruce M Camitta
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

4.  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

Authors:  Stacey L Berg; Susan M Blaney; Meenakshi Devidas; Tom A Lampkin; Anthony Murgo; Mark Bernstein; Amy Billett; Joanne Kurtzberg; Greg Reaman; Paul Gaynon; James Whitlock; Mark Krailo; Michael B Harris
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

5.  Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.

Authors:  Martin H Cohen; John R Johnson; Tristan Massie; Rajeshwari Sridhara; W David McGuinn; Sophia Abraham; Brian P Booth; M Anwar Goheer; David Morse; Xiao H Chen; Nallaperumal Chidambaram; Leslie Kenna; Jogarao V Gobburu; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.

Authors:  D F Kisor; W Plunkett; J Kurtzberg; B Mitchell; J P Hodge; T Ernst; M J Keating; V Gandhi
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

7.  Nelarabine in the treatment of refractory T-cell malignancies.

Authors:  Andrew M Roecker; Amy Stockert; David F Kisor
Journal:  Clin Med Insights Oncol       Date:  2010-12-01

8.  Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.

Authors:  Carlos O Rodriguez; Christine M Stellrecht; Varsha Gandhi
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.

Authors:  V Gandhi; W Plunkett; C O Rodriguez; B J Nowak; M Du; M Ayres; D F Kisor; B S Mitchell; J Kurtzberg; M J Keating
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

10.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Authors:  Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Journal:  Blood       Date:  2007-03-07       Impact factor: 22.113
View more
  18 in total

Review 1.  Relapsed T Cell ALL: Current Approaches and New Directions.

Authors:  Christine M McMahon; Selina M Luger
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

2.  RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.

Authors:  Steffi Gieseler-Halbach; Stefan Meltendorf; Mandy Pierau; Soenke Weinert; Florian H Heidel; Thomas Fischer; Juliane Handschuh; Ruediger C Braun-Dullaeus; Martin Schrappe; Jonathan A Lindquist; Peter R Mertens; Ulrich Thomas; Monika C Brunner-Weinzierl
Journal:  Cell Death Differ       Date:  2016-12-23       Impact factor: 15.828

Review 3.  Progress in adult ALL: incorporation of new agents to frontline treatment.

Authors:  Jessica Leonard; Wendy Stock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Tapan M Kadia; Varsha Gandhi
Journal:  Expert Rev Hematol       Date:  2016-12-08       Impact factor: 2.929

5.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Authors:  Elias J Jabbour; Koji Sasaki; Farhad Ravandi; Nicholas J Short; Guillermo Garcia-Manero; Naval Daver; Tapan Kadia; Marina Konopleva; Nitin Jain; Jorge Cortes; Ghayas C Issa; Jovitta Jacob; Monica Kwari; Philip Thompson; Rebecca Garris; Naveen Pemmaraju; Musa Yilmaz; Susan M O'Brien; Hagop M Kantarjian
Journal:  Cancer       Date:  2019-04-15       Impact factor: 6.860

6.  Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.

Authors:  Preetesh Jain; Hagop Kantarjian; Nitin Jain; Nicholas J Short; Cameron C Yin; Rashmi Kanagal-Shamanna; Joseph Khoury; Marina Konopleva; Koji Sasaki; Tapan M Kadia; Rebecca Garris; Sherry Pierce; Zeev Estrov; William Wierda; Jorge Cortes; Susan O'Brien; Farhad Ravandi; Elias Jabbour
Journal:  Am J Hematol       Date:  2017-07-29       Impact factor: 10.047

Review 7.  Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  Meghavi Kathpalia; Pinki Mishra; Ram Bajpai; Dinesh Bhurani; Nidhi Agarwal
Journal:  Ann Hematol       Date:  2022-06-21       Impact factor: 4.030

8.  Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.

Authors:  X Cahu; M Labopin; S Giebel; M Aljurf; S Kyrcz-Krzemien; G Socié; M Eder; F Bonifazi; D Bunjes; S Vigouroux; M Michallet; M Stelljes; T Zuckerman; J Finke; J Passweg; I Yakoub-Agha; D Niederwieser; G Sucak; H Sengeløv; E Polge; A Nagler; J Esteve; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-11-30       Impact factor: 5.483

9.  Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

Authors:  Nitin Jain; Audrey V Lamb; Susan O'Brien; Farhad Ravandi; Marina Konopleva; Elias Jabbour; Zhuang Zuo; Jeffrey Jorgensen; Pei Lin; Sherry Pierce; Deborah Thomas; Michael Rytting; Gautam Borthakur; Tapan Kadia; Jorge Cortes; Hagop M Kantarjian; Joseph D Khoury
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113

10.  Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Authors:  Annalisa Lonetti; Alessandra Cappellini; Alice Bertaina; Franco Locatelli; Andrea Pession; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; Laura Zambonin; Luca Maria Neri; Alberto Maria Martelli; Francesca Chiarini
Journal:  J Hematol Oncol       Date:  2016-10-24       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.